Ergoteles LLC Acadia Pharmaceuticals Inc Transaction History

Ergoteles LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $285,903 - $411,990	16,062 Added 44.46%	52,188 $1.25 Million
Q1 2023 May 10, 2023	SELL	$16.32 - $20.92 $1.66 Million - $2.12 Million	-101,429 Reduced 73.74%	36,126 $679,000
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $1.71 Million - $2.25 Million	-120,742 Reduced 46.75%	137,555 $2.19 Million
Q3 2022 Nov 14, 2022	BUY	$14.11 - $18.27 $3.4 Million - $4.4 Million	240,741 Added 1371.27%	258,297 $4.23 Million
Q2 2022 Aug 12, 2022	BUY	$13.01 - $27.22 $228,403 - $477,874	17,556 New	17,556 $247,000
Q1 2022 May 13, 2022	SELL	$20.94 - $27.5 $557,778 - $732,517	-26,637 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $70,702 - $114,075	4,211 Added 18.78%	26,637 $622,000
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $353,882 - $555,492	22,426 New	22,426 $372,000
Q2 2021 Aug 12, 2021	SELL	$19.4 - $27.42 $3.14 Million - $4.44 Million	-161,892 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$25.02 - $54.99 $2.45 Million - $5.38 Million	97,758 Added 152.43%	161,892 $4.18 Million
Q4 2020 Feb 11, 2021	BUY	$41.04 - $56.79 $2.63 Million - $3.64 Million	64,134 New	64,134 $3.43 Million

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.